liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
Université de Lorraine, Nancy, France.
European Medicines Agency, Madrid, Spain.
Charité Medical School, Berlin, Germany.
University of Alberta, Edmonton, Canada.
Show others and affiliations
2013 (English)In: European Journal of Heart Failure, ISSN 1388-9842, E-ISSN 1879-0844, Vol. 15, no 10, 1082-1094 p.Article, review/survey (Refereed) Published
Abstract [en]

Endpoint selection is a critically important step in clinical trial design. It poses major challenges for investigators, regulators, and study sponsors, and it also has important clinical and practical implications for physicians and patients. Clinical outcomes of interest in heart failure trials include all-cause mortality, cause-specific mortality, relevant non-fatal morbidity (e.g. all-cause and cause-specific hospitalization), composites capturing both morbidity and mortality, safety, symptoms, functional capacity, and patient-reported outcomes. Each of these endpoints has strengths and weaknesses that create controversies regarding which is most appropriate in terms of clinical importance, sensitivity, reliability, and consistency. Not surprisingly, a lack of consensus exists within the scientific community regarding the optimal endpoint(s) for both acute and chronic heart failure trials. In an effort to address these issues, the Heart Failure Association of the European Society of Cardiology (HFA-ESC) convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists (Nice, France, 1213 February 2012) to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework. This report summarizes the groups recommendations for achieving common views on heart failure endpoints in clinical trials.

Place, publisher, year, edition, pages
Oxford University Press, 2013. Vol. 15, no 10, 1082-1094 p.
Keyword [en]
Heart failure, Morbidity, Mortality, Clinical trials
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-99814DOI: 10.1093/eurjhf/hft095ISI: 000325175700003PubMedID: 23787718OAI: oai:DiVA.org:liu-99814DiVA: diva2:658275
Available from: 2013-10-21 Created: 2013-10-21 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Jaarsma, Tiny

Search in DiVA

By author/editor
Jaarsma, Tiny
By organisation
Division of Health, Activity and CareFaculty of Health Sciences
In the same journal
European Journal of Heart Failure
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 296 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf